How Does Nortriptyline Work?

Nortriptyline, best known in Canada by the brand name Aventyl, is a tricyclic antidepressant (TCA) used primarily to treat depression. It is also commonly prescribed at lower doses, off-label, for neuropathic or nerve pain.

Nortriptyline works mainly by increasing the availability of two neurotransmitters:

Norepinephrine

and, to a lesser degree:

Serotonin

It does this by inhibiting the transporters that normally recycle these neurotransmitters after they are released.

The simplified mechanism is:

Nortriptyline

• Blocks NET — Norepinephrine Transporter
• Blocks SERT — Serotonin Transporter
• Norepinephrine reuptake decreases
• Serotonin reuptake decreases

1. More norepinephrine + serotonin remain available between neurons
2. Adrenergic and serotonin receptors receive altered signaling
3. Mood, attention, motivation and pain-regulating networks adapt
4. Depressive symptoms or neuropathic pain may improve

Nortriptyline is a secondary-amine TCA and has substantially stronger activity at the norepinephrine transporter than at the serotonin transporter. This distinguishes it from amitriptyline, which has a more balanced serotonin-norepinephrine reuptake profile.

How Does Nortriptyline Work for Depression?

Depression should not be understood simply as:

“Low norepinephrine”

or:

“Low serotonin.”

Major depressive disorder can involve dysregulation across several brain networks responsible for:

• Mood
• Motivation
• Reward
• Energy
• Attention
• Working memory
• Stress response
• Emotional regulation
• Sleep
• Negative or repetitive thinking Nortriptyline changes monoamine signaling within these networks.

The process can be represented as:

1. Nortriptyline
2. NET inhibition > SERT inhibition
3. Norepinephrine + serotonin availability increase
4. Adrenergic + serotonin receptor signaling changes
5. Feedback systems gradually adapt
6. Intracellular signaling and neural-network activity change
7. Depressive symptoms may improve

The immediate transporter effect occurs relatively quickly, but the full antidepressant effect takes longer because the nervous system must adapt. The precise mechanism by which nortriptyline ultimately produces mood improvement is still not completely understood.

What Is the Main Target of Nortriptyline?

The most prominent therapeutic target is:

NET — Norepinephrine Transporter

Normally:

1. Norepinephrine is released
2. Norepinephrine activates adrenergic receptors
3. NET transports norepinephrine back into the presynaptic neuron

Nortriptyline inhibits NET.

Therefore:

1. Nortriptyline
2. NET blocked
3. Norepinephrine reuptake decreases
4. Norepinephrine remains available longer
5. Adrenergic receptor signaling increases or changes

Nortriptyline is considerably more noradrenergic than serotonergic compared with many other tricyclic antidepressants.

What Does Norepinephrine Do in the Brain?

Norepinephrine contributes to:

• Attention
• Alertness
• Mental energy
• Motivation
• Working memory
• Stress response
• Cognitive processing
• Pain regulation Appropriately regulated norepinephrine signaling in the:

Prefrontal Cortex — PFC

can support:

• Concentration
• Executive function
• Mental energy
• Goal-directed behaviour Therefore:

1. Nortriptyline
2. NET inhibition
3. Greater norepinephrine availability
4. Prefrontal and mood-related networks receive stronger noradrenergic signaling
5. Energy, concentration and motivation may improve as depression improves

However, more norepinephrine is not automatically better.

Excessive noradrenergic signaling can contribute to:

• Tremor
• Sweating
• Palpitations
• Anxiety
• Restlessness
• Difficulty sleeping The therapeutic goal is appropriate regulation, rather than simply maximizing norepinephrine.

Does Nortriptyline Increase Serotonin?

Yes, but less strongly than norepinephrine.

Nortriptyline also inhibits:

SERT — Serotonin Transporter

Normally:

1. Serotonin is released
2. Serotonin activates receptors
3. SERT transports serotonin back into the neuron

Nortriptyline reduces this reuptake.

Therefore:

1. Nortriptyline
2. SERT inhibition
3. Serotonin clearance decreases
4. Serotonin availability increases
5. Serotonin receptor signaling changes

Nortriptyline therefore influences both major monoamine systems, but its pharmacological profile is more norepinephrine-focused than that of amitriptyline.

Why Is Nortriptyline Called a Secondary-Amine TCA?

Tricyclic antidepressants can broadly be divided into:

Tertiary amines

and:

Secondary amines

Examples of tertiary-amine TCAs include:

• Amitriptyline

• Imipramine Examples of secondary-amine TCAs include:

• Nortriptyline

• Desipramine Secondary amines tend to have relatively greater:

Norepinephrine reuptake inhibition

whereas tertiary amines generally have more pronounced serotonergic activity.

Nortriptyline is therefore pharmacologically closer to a:

Norepinephrine-predominant reuptake inhibitor

than a balanced serotonin-norepinephrine antidepressant.

How Is Nortriptyline Related to Amitriptyline?

Nortriptyline is the principal active secondary-amine metabolite of:

Amitriptyline

The pathway is:

1. Amitriptyline
2. Demethylation — importantly involving CYP2C19
3. Nortriptyline
4. CYP2D6 hydroxylation
5. Hydroxylated metabolites

Amitriptyline and nortriptyline are therefore closely related but pharmacologically distinct.

Amitriptyline

has relatively balanced serotonin and norepinephrine reuptake inhibition.

Nortriptyline

is more strongly norepinephrine-focused.

This also explains why CYP2C19 is highly relevant when amitriptyline is prescribed, whereas CYP2D6 is the principal actionable pharmacogenetic enzyme when nortriptyline itself is prescribed.

Does Nortriptyline Affect Dopamine?

Nortriptyline is not primarily a dopamine transporter inhibitor and does not directly stimulate dopamine receptors.

Its principal monoamine actions are:

Norepinephrine

and:

Serotonin

However, these neurotransmitter systems interact with dopamine pathways.

In the prefrontal cortex, NET also participates in catecholamine regulation, so strong NET inhibition can indirectly influence the local dopamine environment.

That should be considered a:

Secondary downstream effect

rather than the primary mechanism of nortriptyline.

For clinical purposes, nortriptyline is best described as:

NET-predominant with additional SERT inhibition

rather than as a dopamine-enhancing antidepressant.

Why Does Nortriptyline Take Several Weeks to Work for Depression?

Nortriptyline begins inhibiting NET and SERT relatively soon after reaching the brain.

But transporter blockade is only the first step.

The longer process is:

1. NET + SERT inhibited
2. Norepinephrine + serotonin signaling changes
3. Adrenergic and serotonin receptors are repeatedly exposed to altered neurotransmission
4. Receptor sensitivity and feedback mechanisms adapt
5. Second-messenger and gene-expression systems change
6. Neural networks gradually reorganize
7. Clinical antidepressant improvement develops

Research on TCAs describes downstream changes including altered adrenergic and serotonin receptor regulation in addition to their immediate monoamine-reuptake effects.

This is why:

Nortriptyline can change neurotransmitter signaling quickly, while meaningful improvement in depression may take several weeks.

How Does Nortriptyline Work for Nerve Pain?

Nortriptyline is also frequently prescribed off-label for:

Neuropathic Pain

Neuropathic pain occurs when the nervous system itself becomes damaged or abnormally excitable.

Symptoms can include:

• Burning pain
• Shooting pain
• Electric-shock sensations
• Tingling
• Pain from light touch
• Persistent nerve sensitivity Nortriptyline’s analgesic effect is not simply a consequence of treating depression.

It can reduce pain even when a patient is not depressed.

Why Does Norepinephrine Help Reduce Neuropathic Pain?

The brain has pathways that travel downward into the spinal cord and help suppress incoming pain signals.

These are called:

Descending Inhibitory Pain Pathways

Norepinephrine is particularly important in these systems.

The simplified pathway is:

1. Nortriptyline
2. NET inhibition
3. Norepinephrine increases in pain-regulating pathways
4. Descending noradrenergic inhibition becomes stronger
5. α2 adrenergic receptors in the spinal cord are activated
6. Transmission of pain signals is reduced
7. Neuropathic pain may improve

Reviews of neuropathic-pain pharmacology identify increased spinal norepinephrine and strengthened descending inhibitory signaling as an important mechanism underlying TCA analgesia.

Does Serotonin Also Contribute to Nortriptyline’s Pain Effect?

Probably, although norepinephrine appears especially important for nortriptyline.

Descending pain-regulation pathways use both:

Norepinephrine

and:

Serotonin

TCAs can increase both by preventing their reuptake.

Therefore:

1. Nortriptyline
2. ↑ NE + ↑ 5-HT in descending pain pathways
3. Spinal pain transmission is modulated
4. Pain perception may decrease

The serotonin component of pain modulation is complex because different serotonin receptor subtypes can either inhibit or facilitate pain depending on the pathway.

Does Nortriptyline Affect Sodium Channels?

Yes, TCAs can also inhibit:

Voltage-gated sodium channels

particularly at higher concentrations.

Sodium channels are essential for:

Electrical impulse transmission along nerves

In neuropathic pain, injured nerves can become excessively excitable and generate abnormal electrical impulses.

Therefore:

1. Nortriptyline
2. Some sodium-channel blockade
3. Abnormal nerve firing may decrease
4. Potential additional analgesic effect

Sodium-channel blockade is considered one of several secondary mechanisms that may contribute to TCA analgesia.

However, the same ion-channel effects become clinically important in TCA overdose, where excessive sodium-channel blockade can disrupt cardiac electrical conduction.

Why Can Nortriptyline Help Pain at Lower Doses Than Depression?

The mechanisms required to reduce neuropathic pain are not necessarily identical to those required for a full antidepressant effect.

Pain pathways in the:

• Brainstem
• Spinal cord
• Peripheral nervous system can respond to increased noradrenergic signaling at relatively low doses.

This is why nortriptyline is often prescribed at lower doses for neuropathic pain than for depression.

Importantly, the CPIC pharmacogenomic recommendations for higher-dose TCA treatment of depression should not automatically be applied in the same way to low-dose neuropathic-pain treatment.

Why Does Nortriptyline Cause Dry Mouth?

Nortriptyline does more than inhibit NET and SERT.

It also antagonizes:

Muscarinic Acetylcholine Receptors

Acetylcholine helps regulate:

• Saliva production
• Intestinal motility
• Bladder contraction
• Eye focusing
• Cognitive function Therefore:

1. Nortriptyline
2. Muscarinic receptor blockade
3. Possible:

• Dry mouth
• Constipation
• Blurred vision
• Urinary retention These are known as:

Anticholinergic Side Effects

Nortriptyline’s activity at acetylcholine receptors is part of the broader receptor pharmacology characteristic of TCAs.

Why Does Nortriptyline Cause Constipation?

Acetylcholine normally helps stimulate:

Intestinal movement

When muscarinic signaling is blocked:

1. Nortriptyline
2. Muscarinic receptor blockade
3. Gastrointestinal movement slows
4. Constipation

This effect becomes more clinically important in:

• Older adults
• People already prone to constipation
• Patients taking other anticholinergic medications

Why Can Nortriptyline Cause Difficulty Urinating?

The bladder depends on acetylcholine to contract properly.

Therefore:

1. Nortriptyline
2. Muscarinic blockade
3. Bladder contraction becomes less efficient
4. Difficulty emptying the bladder

Possible symptoms include:

• Hesitation
• Weak urinary stream
• Incomplete emptying
• Urinary retention This is particularly relevant in people with:

Prostate enlargement or existing urinary obstruction.

Why Can Nortriptyline Cause Drowsiness?

Nortriptyline can antagonize:

Histamine H1 Receptors

Histamine helps maintain:

• Wakefulness
• Alertness
• Arousal Therefore:

1. Nortriptyline
2. H1 blockade
3. Histamine-mediated wakefulness decreases
4. Sleepiness or sedation

Nortriptyline is generally less sedating than some tertiary-amine TCAs such as amitriptyline, but meaningful sedation can still occur. Secondary-amine TCAs are often better tolerated in terms of sedation and anticholinergic effects than tertiary amines.

Why Can Nortriptyline Cause Dizziness When Standing?

Nortriptyline can also antagonize:

Alpha-1 Adrenergic Receptors

Alpha-1 receptors help blood vessels constrict when a person stands up.

Therefore:

1. Nortriptyline
2. α1 signaling decreases
3. Blood vessels may not constrict as effectively
4. Blood pressure falls when standing
5. Dizziness or lightheadedness

This is called:

Orthostatic Hypotension

This mechanism is especially important in older adults and people taking other medications that lower blood pressure.

Why Can Nortriptyline Affect the Heart?

TCAs can influence several aspects of cardiac electrophysiology.

At higher concentrations, nortriptyline can affect:

Cardiac sodium channels

and other ion-channel systems.

Excessive exposure can therefore slow electrical conduction and increase the risk of:

• Conduction abnormalities
• Arrhythmias
• Tachycardia
• QT-related abnormalities in susceptible patients The broader pharmacology of nortriptyline includes sodium-channel blockade in addition to its monoamine and receptor effects.

This is one reason nortriptyline has a much narrower safety margin in overdose than modern SSRIs.

Why Does Nortriptyline Have More Side Effects Than an SSRI?

An SSRI is comparatively selective.

For example:

Escitalopram

primarily targets:

SERT Nortriptyline interacts with several systems:

• NET therapeutic norepinephrine effect

• SERT serotonin effect

• Muscarinic receptors anticholinergic effects

• H1 receptors sedation

• Alpha-adrenergic receptors orthostatic effects

• Ion channels cardiac and neurological effects at higher exposure

This broader pharmacology can provide useful therapeutic effects, but it also creates more opportunities for adverse effects.

How Is Nortriptyline Different from Amitriptyline?

The two medications belong to the same family but have meaningful pharmacological differences.

Amitriptyline

is a:

Tertiary-amine TCA

with relatively strong:

SERT + NET inhibition

and substantial:

anticholinergic + antihistamine effects

Nortriptyline

is a:

Secondary-amine TCA

with:

NET inhibition >> SERT inhibition

and generally somewhat less:

sedation + anticholinergic burden

than amitriptyline.

A simplified comparison is:

Amitriptyline

→ more balanced serotonin + norepinephrine effect→ generally more sedating/anticholinergic

Nortriptyline

→ more norepinephrine-focused→ generally somewhat better tolerated

Individual responses still vary considerably.

How Is Nortriptyline Different From an SNRI?

An SNRI such as:

• Duloxetine
• Venlafaxine
• Levomilnacipran also inhibits:

NET + SERT

So why is nortriptyline not simply called an SNRI?

Because classification reflects more than these two transporters.

Modern SNRIs are relatively selective for monoamine transporters.

Nortriptyline belongs to the TCA family and additionally affects:

• Muscarinic receptors
• Histamine receptors
• Adrenergic receptors
• Ion channels Therefore:

SNRI

primarily:

NET + SERT inhibition

while:

Nortriptyline

• NET-predominant reuptake inhibition
• SERT inhibition

broader receptor and ion-channel effects

This difference explains much of the difference in side-effect and overdose profiles.

How Is Nortriptyline Different from Duloxetine for Nerve Pain?

Both medications can improve neuropathic pain partly through increased:

Descending norepinephrine signaling

However:

Duloxetine

is a relatively selective SNRI.

Nortriptyline

is a TCA with broader receptor effects.

Therefore, nortriptyline may cause more:

• Dry mouth
• Constipation
• Urinary difficulty
• Orthostatic hypotension
• Cardiac effects while duloxetine has its own distinct adverse-effect and metabolic profile.

Neither mechanism is automatically better for every patient.

Why Can the Same Nortriptyline Dose Affect Two People Very Differently?

This is particularly important with nortriptyline.

Two people taking exactly the same dose may have very different:

Blood concentrations

One may have:

Good response with few side effects

another:

Dry mouth + dizziness + sedation + cardiac concerns

and another:

Little benefit because concentrations are too low

A major reason is:

CYP2D6

How Is Nortriptyline Metabolized?

The principal pharmacogenetically important enzyme is:

CYP2D6

Nortriptyline undergoes hydroxylation to:

10-hydroxynortriptyline

The pathway can be simplified as:

1. Nortriptyline
2. CYP2D6
3. 10-hydroxynortriptyline
4. Further metabolism and elimination

CYP2D6 variability is clinically important enough that CPIC provides formal genotype-based recommendations for nortriptyline used at antidepressant doses.

Why Is CYP2D6 So Important for Nortriptyline?

CYP2D6 activity varies greatly between people because of inherited genetic differences.

A person may be:

• CYP2D6 Poor Metabolizer
• Intermediate Metabolizer
• Normal Metabolizer
• Ultrarapid Metabolizer The consequences can be substantial.

CYP2D6 Poor Metabolizer and Nortriptyline

A CYP2D6 Poor Metabolizer has very little functional CYP2D6 activity.

Therefore:

1. Low CYP2D6 activity
2. Nortriptyline hydroxylation decreases
3. Nortriptyline clearance decreases
4. Nortriptyline concentration increases
5. Potential increase in:

• Dry mouth
• Constipation
• Sedation
• Dizziness
• Cardiovascular effects
• Other concentration-related adverse effects For depression-level dosing, CPIC recommends avoiding a TCA if a suitable alternative is available because of the increased probability of side effects. If nortriptyline is still used, CPIC recommends considering approximately a 50% lower starting dose with therapeutic drug monitoring.

CYP2D6 Intermediate Metabolizer and Nortriptyline

A CYP2D6 Intermediate Metabolizer has reduced enzyme activity.

Therefore:

1. Reduced CYP2D6
2. Nortriptyline metabolism slows
3. Drug exposure increases

CPIC recommends considering approximately:

25% lower than the usual starting dose

for higher-dose treatment such as depression, with:

Therapeutic Drug Monitoring — TDM

to guide subsequent adjustment.

CYP2D6 Normal Metabolizer and Nortriptyline

A CYP2D6 Normal Metabolizer is expected to have typical CYP2D6 activity.

CPIC recommends:

Use the standard recommended starting dose

followed by adjustment based on:

• Clinical response
• Side effects
• Plasma concentration when appropriate. Normal metabolism does not guarantee that nortriptyline will work.

It only suggests that CYP2D6-related exposure is unlikely to be unusually high or low.

CYP2D6 Ultrarapid Metabolizer and Nortriptyline

An Ultrarapid Metabolizer has increased CYP2D6 activity.

Therefore:

1. High CYP2D6 activity
2. Nortriptyline metabolism increases
3. Nortriptyline concentration may become too low
4. Treatment failure becomes more likely

CPIC recommends preferably choosing an alternative medication not dependent on CYP2D6. If nortriptyline is still used, a higher target dose may sometimes be necessary, but no simple fixed dose multiplier is recommended; therapeutic drug monitoring should guide adjustment.

This distinction matters because aggressively increasing nortriptyline can also generate high concentrations of hydroxylated metabolites.

Why Is Therapeutic Drug Monitoring Useful with Nortriptyline?

Nortriptyline is one of the antidepressants where measuring the actual blood concentration can be clinically useful.

This is called:

Therapeutic Drug Monitoring — TDM

The principle is:

1. Nortriptyline dose
2. CYP2D6 metabolism + drug interactions + individual physiology
3. Actual plasma concentration

Instead of assuming that:

“75 mg means the same exposure in everyone,”

TDM can show whether the patient’s actual concentration is:

• Lower than expected

• Within the desired range

• Higher than expected TDM becomes particularly useful when:

• CYP2D6 phenotype is unusual

• A CYP2D6 inhibitor is present

• Side effects are unexpectedly severe

• Response is unexpectedly poor

• Higher doses are being considered CPIC specifically recommends therapeutic drug monitoring when nortriptyline is used in CYP2D6 Intermediate, Poor or Ultrarapid Metabolizers.

What Is Phenoconversion with Nortriptyline?

Genetics does not always equal actual enzyme activity.

For example, someone may genetically be a:

CYP2D6 Normal Metabolizer

but take:

Fluoxetine Paroxetine

or:

Bupropion

which can strongly inhibit CYP2D6.

The result can be:

1. CYP2D6 Normal genotype
2. Strong CYP2D6 inhibitor introduced
3. Functional CYP2D6 activity decreases
4. Nortriptyline metabolism slows
5. Nortriptyline concentration rises

This is called: Phenoconversion

For nortriptyline, phenoconversion is particularly important because CYP2D6 has such a large effect on exposure.

A useful pharmacogenomic interpretation should therefore consider:

Genetics + current medications

rather than genetics alone.

Does CYP2C19 Affect Nortriptyline?

Not in the same clinically important way as CYP2D6 when nortriptyline itself is being prescribed.

CYP2C19 is very important when the patient takes:

Amitriptyline

because CYP2C19 contributes to:

1. Amitriptyline
2. Nortriptyline

But direct nortriptyline therapy bypasses that conversion step.

CPIC specifically identifies nortriptyline as a secondary-amine TCA without major CYP2C19 metabolism.

Therefore:

CYP2D6 is the principal actionable pharmacokinetic gene for directly administered nortriptyline.

Can Nortriptyline Fail Even When CYP2D6 Metabolism Is Normal?

Yes.

This is where the distinction between:

Pharmacokinetics — PK

and:

Pharmacodynamics — PD

becomes important.

A normal CYP2D6 result can tell us that drug metabolism is likely to be relatively typical.

It cannot tell us whether the medication’s norepinephrine-serotonin mechanism is biologically optimal for that patient.

Nortriptyline Pharmacokinetics — PK

PK asks: Does an appropriate amount of nortriptyline reach the brain?

The pathway is:

1. Nortriptyline dose
2. Absorption
3. CYP2D6 metabolism
4. Nortriptyline concentration
5. Medication reaches the brain

Important variables include:

• CYP2D6 genotype
• CYP2D6 inhibitors
• Dose
• Age
• Liver function
• Adherence
• Drug interactions PK determines: How much nortriptyline is available to act on NET and SERT.

Nortriptyline Pharmacodynamics — PD

PD asks: What does the brain do with that nortriptyline concentration?

Nortriptyline

• NET / SLC6A2 inhibition
• SERT / SLC6A4 inhibition

1. ↑ Norepinephrine + ↑ serotonin availability
2. Adrenergic + serotonin receptors respond
3. Mood, cognitive and pain-control networks adapt
4. Symptoms may improve

At the same time:

Muscarinic blockade

→ dry mouth, constipation, blurred vision, urinary retention

H1 blockade

→ sedation

Alpha-adrenergic blockade

→ orthostatic hypotension

Ion-channel effects

→ cardiac risk at excessive exposure

Therefore:

Normal nortriptyline pharmacokinetics do not automatically mean optimal pharmacodynamic response.

Nortriptyline Requires Both Appropriate Drug Exposure and Brain Compatibility

The complete pathway can be summarized as:

1. Nortriptyline is taken
2. PK — Pharmacokinetics
3. Absorption
4. CYP2D6 metabolism
5. Drug interactions / phenoconversion
6. Appropriate nortriptyline concentration
7. PD — Pharmacodynamics
8. NET inhibition > SERT inhibition
9. ↑ Norepinephrine + ↑ serotonin availability
10. Adrenergic + serotonin receptors respond
11. Mood, cognitive and pain-regulating networks adapt
12. Depression or neuropathic pain may improve

At the same time:

Muscarinic receptors

→ anticholinergic effects

H1 receptors

→ sedation

Alpha-adrenergic receptors

→ orthostatic effects

Ion channels

→ greater cardiac concern at excessive exposure

This produces two different personalized-prescribing questions:

PK asks:

Does an appropriate amount of nortriptyline reach the brain?

PD asks: Is nortriptyline’s predominantly noradrenergic mechanism compatible with this patient’s underlying biology and symptoms?

Both matter.

What Is the Role of SLC6A2 Genetics?

SLC6A2 encodes: NET — Norepinephrine Transporter

which is nortriptyline’s dominant monoamine-transporter target.

The biological relationship is direct:

1. SLC6A2
2. NET expression and function
3. Nortriptyline inhibits NET
4. Norepinephrine signaling changes
5. Potential antidepressant and analgesic response

This makes SLC6A2 biologically relevant to nortriptyline pharmacodynamics.

However:

There is currently no validated SLC6A2 genotype-based nortriptyline dosing or selection guideline.

An SLC6A2 result should therefore not independently be interpreted as:

“Nortriptyline will work”

or:

“Nortriptyline will fail.”

What Is the Role of SLC6A4 Genetics?

SLC6A4 encodes: SERT — Serotonin Transporter

Nortriptyline also inhibits SERT, although less strongly than NET.

Variants including:

5-HTTLPR

and:

rs25531

can influence aspects of serotonin transporter biology and have been studied extensively in antidepressant response.

However:

SLC6A4 is not an established genotype-based nortriptyline prescribing marker.

Its evidence is much less clinically actionable than the CYP2D6-nortriptyline relationship.

What About ADRA2A Genetics?

ADRA2A encodes the: Alpha-2A Adrenergic Receptor

Nortriptyline does not directly target alpha-2A in the way guanfacine does.

Instead:

1. Nortriptyline inhibits NET
2. Norepinephrine availability increases
3. Norepinephrine acts on adrenergic receptors including α2A

This makes ADRA2A a plausible downstream pharmacodynamic modifier.

But currently:

There is no validated ADRA2A-based nortriptyline prescribing guideline.

What About HTR2A and HTR2C Genetics?

Once serotonin availability increases, serotonin interacts with many receptor types, including:

• 5-HT2A encoded by: HTR2A

• 5-HT2C encoded by: HTR2C These receptors participate in:

• Mood

• Anxiety

• Sleep

• Emotional processing

• Appetite

• Dopamine and norepinephrine regulation However, nortriptyline response is not determined by one serotonin receptor.

There is currently:

No validated HTR2A- or HTR2C-guided nortriptyline prescribing recommendation.

What About COMT Genetics?

COMT

helps metabolize catecholamines, particularly dopamine and norepinephrine in certain brain regions.

The common:

COMT rs4680 — Val158Met

variant alters COMT activity.

Because nortriptyline strongly increases norepinephrine availability, COMT is biologically relevant to the broader catecholamine environment.

However:

COMT genotype does not currently provide an established nortriptyline dosing or efficacy recommendation.

Can Pharmacogenomic Testing Predict Whether Nortriptyline Will Work?

It can provide clinically useful information, but not certainty.

Nortriptyline is a particularly good example because its pharmacogenomics has two very different evidence levels.

Strongest established evidence: CYP2D6

CYP2D6 can meaningfully affect:

• Nortriptyline concentration
• Side-effect risk
• Risk of insufficient exposure and CPIC provides formal dosing recommendations.

Emerging pharmacodynamic evidence

Genes such as:

• SLC6A2
• SLC6A4
• ADRA2A
• HTR2A
• HTR2C
• COMT may contribute biologically to how the brain responds, but none currently has a validated stand-alone nortriptyline prescribing guideline.

Therefore:

CYP2D6 can help determine whether nortriptyline exposure is likely to be appropriate, but it cannot by itself determine whether nortriptyline’s mechanism is optimal for the patient’s depression or pain.

Why Might Nortriptyline Work Very Well for One Person but Poorly for Another?

Two people can both have depression but have very different symptom patterns.

One may experience:

Low energy + poor concentration + reduced motivation

Another may primarily experience:

Anxiety + insomnia + hyperarousal

Another may experience:

Pain + depression

Another may have:

Significant sensitivity to anticholinergic side effects

Nortriptyline’s strong noradrenergic profile may be helpful for some symptom patterns but less compatible with others.

At the same time, CYP2D6 can change the amount of drug reaching the brain.

Therefore, treatment response depends on both:

How much drug reaches the target

and:

Whether the target mechanism fits the patient’s biology.